1. 上海中医药大学附属龙华医院
2. 上海交通大学附属胸科医院
纸质出版:2015
移动端阅览
[1]刘苓霜,刘嘉湘,沈丽萍,姜怡,顾爱琴.中医辨证治疗对晚期非小细胞肺癌巩固治疗的影响[J].中医杂志,2015,56(17):1473-1478.
LIU Lingshuang, LIU Jiaxiang, SHEN Liping, et al. Effects of TCM Syndrome Differentiation and Treatment on Consolidation Treatment of Advanced Non-small Cell Lung Cancer[J]. Journal of Traditional Chinese Medicine2015, 56(17): 1473-1478.
[1]刘苓霜,刘嘉湘,沈丽萍,姜怡,顾爱琴.中医辨证治疗对晚期非小细胞肺癌巩固治疗的影响[J].中医杂志,2015,56(17):1473-1478. DOI: 10.13288/j.11-2166/r.2015.17.010.
LIU Lingshuang, LIU Jiaxiang, SHEN Liping, et al. Effects of TCM Syndrome Differentiation and Treatment on Consolidation Treatment of Advanced Non-small Cell Lung Cancer[J]. Journal of Traditional Chinese Medicine2015, 56(17): 1473-1478. DOI: 10.13288/j.11-2166/r.2015.17.010.
目的观察中医辨证治疗在晚期非小细胞肺癌巩固治疗中的作用。方法 72例晚期非小细胞肺癌一线化疗后疾病无进展者随机分为治疗组和对照组各36例
治疗组患者辨证分为阴虚内热证、脾虚痰湿证、气阴两虚证并给予相应中药治疗
对照组仅观察不进行任何抗肿瘤治疗
两组治疗或观察以28天为1个周期
直至患者出现疾病进展或不可耐受的毒副反应。比较两组患者疾病进展时间、一年生存率
采用欧洲癌症研究与治疗组织的肺癌患者生存质量特异量表(EORTC QLQ-LC43)进行生存质量测定
治疗或观察后判定中医症状疗效、体力状况疗效及肿瘤客观疗效。结果治疗组中位疾病进展时间为87天
对照组为66天
两组比较差异有统计学意义(P<0.05)。治疗组一年生存率为67.64%
对照组为68.75%
两组比较差异无统计学意义(P>0.05)。生活质量方面:治疗组治疗后在躯体功能、情绪功能、总健康状况较治疗前评分升高
食欲丧失、气促、咳嗽评分较治疗前下降(P<0.05)。对照组观察后躯体功能、社会功能领域、总健康状况评分较观察前下降
疲倦、气促、咯血、咳嗽、其他部位痛评分升高(P<0.05)。治疗组治疗后中医症状积分较治疗前积分下降
对照组观察后较治疗前上升
治疗后治疗组中医症状积分低于对照组(P<0.05)。治疗组体力状况疗效、肿瘤客观疗效均优于对照组(P<0.01)。结论中医辨证治疗运用于晚期非小细胞肺癌一线化疗后具有延长疾病进展、稳定病灶、改善症状、提高体力状况和生活质量等方面的作用
可巩固化疗疗效。
Objective To observe effects of TCM syndrome differentiation and treatment on consolidation treatment of advanced non-small cell lung cancer. Methods Seventy-two cases of advanced non-small cell lung cancers with progression-free disease after first-line chemotherapy were randomly divided into treatment group and control group
with 36 cases in each group. In the treatment group
patients were made syndrome differentiation to internal heat due to Yin deficiency syndrome
phlegm-dampness due to spleen deficiency syndrome and deficiency of both Qi and Yin syndrome
and given the corresponding Chinese medicine. The control group only was not given anti-tumor treatments. Both groups were treated or observed for 28 days as a cycle until progressive disease or intolerant toxic and side effects occurred. Compared two groups of patients with disease progression time and one year survival rate and used the specific scale about lung-cancer patients’ quality of life of the European organization for research and treatment of cancer( EORTC QLQ-LC43) to measure quality of life. Evaluated efficacy of TCM symptom
physical condition and objective cancer after treatment or observation. Results The median time to progression( MTTP) of the treatment group was 87 days
but that of the control group was 66 days. Differences of the two groups were statisticallysignificant( P < 0. 05). The one year survival rate of the treatment group was 67. 64%
but that of the control group was 68. 75%. The differences were not statistically significant( P > 0. 05). Quality of life: in the treatment group
after treatment
the scores of physical function
emotional function and general state of health were higher than those before treatment
but the scores of loss of appetite
shortness of breath and cough were lower than those before treatment( P < 0. 05). In the control group
after observation
the scores of the physical function
social function and general state of health were lower than those before observation
but the scores of fatigue
shortness of breath
hemoptysis
cough and pain in other parts score higher in other parts were higher than those before observation( P < 0. 05).The TCM symptom score of the treatment group after treatment was lower than that before treatment
but that of the control group after observation was higher than that before observation. After treatment
the TCM symptom score of the treatment group was lower than the control group( P < 0. 05). The efficacy of physical condition and objective cancer in the treatment group were better than that of the control group( P < 0. 01). Conclusion Using the TCM syndrome differentiation and treatment after the first-line chemotherapy of terminal non-small cell lung cancer may delay the disease progress
stabilize nidus
improve symptoms
physical condition and quality of life and so on
also can consolidate curative effect of chemotherapy.
0
浏览量
522
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号